Your browser doesn't support javascript.
loading
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Acta Pharmaceutica Sinica B ; (6): 503-510, 2018.
Artigo em Inglês | WPRIM | ID: wpr-690888
ABSTRACT
HER3 belongs to the human epidermal growth factor receptor (HER) family which also includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the HER family, HER3 lacks or has little intrinsic tyrosine kinase activity. It frequently co-expresses and forms heterodimers with other receptor tyrosine kinases (RTKs) in cancer cells to activate oncogenic signaling, especially the PI-3K/Akt pathway and Src kinase. Elevated expression of HER3 has been observed in a wide variety of human cancers and associates with a worse survival in cancer patients with solid tumors. Studies on the underlying mechanism implicate HER3 expression as a major cause of treatment failure in cancer therapy. Activation of HER3 signaling has also been shown to promote cancer metastasis. These data strongly support the notion that therapeutic inactivation of HER3 and/or its downstream signaling is required to overcome treatment resistance and improve the outcomes of cancer patients.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Inglês Revista: Acta Pharmaceutica Sinica B Ano de publicação: 2018 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Inglês Revista: Acta Pharmaceutica Sinica B Ano de publicação: 2018 Tipo de documento: Artigo